Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

12-12-2025(Fri) 11-12-2025(Thu) 10-12-2025(Wed) 09-12-2025(Tue) 08-12-2025(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
23 Apr, 2026 (Thursday)

            
YIDU TECH(2158)
Analysis¡G
Yidu Tech has long been deeply engaged in the field of medical intelligence. Built on a full-chain ecosystem covering ¡§medicine ¡V pharmaceuticals ¡V insurance ¡V patients,¡¨ the Group is accelerating the deep integration of large model technology with real-world medical scenarios. It is actively participating in the construction of an inclusive, efficient, and collaborative medical AI infrastructure, and continues to lead innovation as the industry shifts from building technological capabilities to a new phase of systematic empowerment.The Group¡¦s core algorithmic engine, the ¡§AI Medical Brain¡¨ YiduCore, operates through a reinforced closed loop of ¡§data-driven algorithms, algorithms empowering scenarios, and scenarios feeding back into data.¡¨ This continuously improves the precision of medical insights and the intelligence level of its algorithms, creating a flywheel effect in which ¡§technology ¡V application ¡V data¡¨ mutually reinforce one another. YiduCore simulates the autonomous learning process of a human doctor¡¦s brain, replicating the full journey from information collection and deep reasoning to decision-making. It emulates doctors¡¦ thinking patterns and logical pathways in disease diagnosis, treatment selection, and public health management, enabling its performance across diverse scenarios to more closely align with real-world physician behavior.In the first half of the year ended 30 September 2025, the Group provided solutions to 127 top-tier hospitals in China and 44 regulatory bodies and policymakers, with cumulative coverage exceeding 10,000 hospitals. Its large model technology has helped multiple hospitals upgrade their data governance and research platforms. Clinical research has been deepened and expanded across multiple disciplines including oncology, respiratory medicine, and traditional Chinese medicine. The Doctor Copilot product matrix now covers the entire diagnosis and treatment process, with usage exceeding 50,000 times per hospital. The AI middleware platform has further supported innovative applications in multiple hospitals and medical aesthetics scenarios. The number of life sciences clients served by the Group reached 88. Among the top 20 multinational pharmaceutical companies, 17 are customers of the Group.
In the health management platform and solutions segment, the Group maintains a leading position in core cities. It has served as the main operating platform for ¡§Shenzhen Huimin Insurance¡¨ for three consecutive years and for ¡§Beijing Huimin Insurance¡¨ for five consecutive years. The insured volume of ¡§Shenzhen Huimin Insurance¡¨ hit a new record, with the number of policyholders exceeding 6.15 million. Over the past three years, it has cumulatively served more than 18 million person-times. User brand loyalty continues to rise, with the number of active users who have completed at least one transaction on the health management platform exceeding 22 million.
The Group recently issued a profit alert, expecting net profit for the financial year ending 31 March 2026 to be between approximately RMB 55 million and RMB 70 million, compared with a net loss of RMB 135 million in the financial year ended 31 March 2025. (For the 2026 financial year, profit attributable to shareholders is expected to range from approximately RMB 41 million to RMB 56 million, versus a loss attributable to shareholders of approximately RMB 117 million in the 2025 financial year.). The improvement was mainly due to the continuous upgrading of the Group¡¦s products after integrating AI capabilities, which enhanced the value proposition and competitiveness of its offerings. This led to a significant increase in new orders in the core business segments and an improvement in gross margin. The upgraded AI-integrated products deliver higher added value, coupled with improved operational efficiency and economies of scale.(I do not hold the above stock)
Strategy¡G
Buy-in Price: $6.10, Target Price: $7.00, Cut Loss Price: $5.80


XIAMEN TUNGSTEN(600549)
Analysis¡G
Xiamen Tungsten operates three major businesses: "tungsten-molybdenum, rare earth, and cathode materials." It is currently a globally leading tungsten smelting and processing enterprise, as well as a world-class large-scale tungsten powder production base with a complete tungsten industrial chain. Fine tungsten wire accounts for over 80% of the market share in the photovoltaic sector. Additionally, the company is one of China's four major rare earth groups, boasting a comprehensive rare earth industrial chain. Its primary deep-processed product, magnetic materials, has achieved growth in multiple application fields such as new energy vehicles and energy-saving home appliances, while also obtaining certifications from multiple clients in the humanoid robotics sector. The company is also a producer of lithium-ion battery cathode materials, manufacturing lithium cobalt oxide, ternary, and lithium iron phosphate. According to its FY2025 positive alert, the total revenue reached 46.469 billion yuan, marking a yoy increase of 31.37%, with a net profit of 2.311 billion yuan, up 35.08% yoy. The significant performance growth was primarily driven by rising prices and increased sales of tungsten and rare earth products, leading to a substantial improvement in profitability. The Company's "New Materials + New Energy" platform demonstrates significant development potential, with its three major businesses expected to continue advancing in parallel in the future.
Strategy¡G
Buy-in Price: $64.90, Target Price: $73.00, Cut Loss Price: $60.00



Geely (175.HK) - Accelerating Overseas Expansion and Premiumisation Strategy

Company Profile

Geely is one of the leading enterprises in China's self-brand passenger vehicles manufacturers. The Company's products include six major brands, Geely, Lynk & Co, Zeekr, covering the A0 to C-class passenger vehicles market.

Investment Summary

26Q1 Sales Remained Largely Flat, with Premiumisation Strategy Showing Bright Spots. In the first quarter of 2026, Geely Auto delivered a cumulative 709.4 thousand vehicles, up 0.8% yoy, setting a new record high for the same period in history and regaining the top position among domestic brands. Among them, Geely brand's China Star recorded Q1 sales of 312 thousand units, down 5.5% yoy, while Galaxy sold 239 thousand units, down 8.0% yoy.

Among the sub-brands, the premium brands delivered standout performance: LYNK&CO sold 82 thousand units, up 12.5% yoy, while Zeekr sold 77 thousand units, up 86.1% yoy. The premium SUV model Zeekr 9X achieved a smooth ramp-up, with cumulative Q1 sales exceeding 20 thousand units and March sales surpassing 10 thousand units. It is the Company's first full-size premium SUV equipped with Super Hybrid technology, and also the first to feature the SEA AI Digital Chassis and the G-Pilot H9 intelligent assisted driving system.

With an average selling price of over RMB 530 thousand, it has significantly enhanced brand strength and the profitability potential following scale-up. We believe that the launch of flagship 9-series models, such as the LYNK&CO 900, Zeekr 9X and Galaxy M9, marks the beginning of a new chapter in the Company's premiumisation strategy in the SUV segment.

Explosive Growth in Exports

In overseas markets, Geely Auto recorded cumulative exports of 203 thousand units in Q1, up 125.7% yoy, far exceeding the industry's average growth rate of 56.7%, representing explosive growth and accounting for 28.6% of total sales. In the European market, the Company has completed brand layout in five core countries¡XSpain, Germany, the Netherlands, Belgium and Luxembourg. In the Southeast Asian market, Geely Xingyuan has commenced deliveries and is gradually advancing localised production.

In Latin America and the Middle East, the LYNK&CO and Zeekr brands are accelerating market penetration. The Company has provided 2026 full-year export sales guidance of no less than 640 thousand units, with a target of 750 thousand units, equivalent to yoy growth of 52.4% to 78.6%. Export business is expected to become the most important growth driver this year.

We believe that the rapid volume expansion and high profitability of overseas markets will help offset the slowdown in domestic sales and improve profit margins.

New Energy Vehicles Account for Over Half

Geely Auto's new energy transition is entering an accelerated phase. In Q1 2026, the Company's cumulative sales of new energy vehicles reached 369.1 thousand units, up 9% yoy, with the penetration rate rising to 52%, and further increasing to 55% in March alone. From a structural perspective, plug-in hybrid models contributed more incremental growth within Geely's new energy product portfolio, up 62% yoy and currently accounting for 44%, while pure electric models declined by 13% yoy, accounting for 56%.

Recent geopolitical conflicts in the Middle East have led to volatility in oil prices, which has objectively accelerated the global adoption of electric vehicles. In the long term, this trend benefits leading automakers with advantages in products, technology, cost, and supply chains. The Company's new energy vehicle segment is expected to achieve a favourable trajectory of simultaneous volume and profit growth.

Strong Performance Last Year, Core Net Profit up 36%

According to the Company's 2025 annual report, full-year revenue reached RMB 345,232 million, up 25.1% yoy; net profit attributable to the parent company was RMB 16,852 million, up 0.2% yoy. Excluding foreign exchange gains, impairment losses, and gains from the deemed disposal of subsidiaries in 2024, core net profit attributable to the parent company amounted to RMB 14.41 billion, up 36% yoy.

The strong performance was mainly driven by robust sales growth, which led to the release of scale effects, as well as optimisation of product mix and synergies from strategic integration. In 2025, the Company recorded cumulative sales of 3,024.6 thousand units, up 39.0% yoy, of which new energy vehicle sales reached 1,687.8 thousand units, up 90.0% yoy. Gross margin in 2025 was 16.61%, up 0.1 ppts yoy; core net profit margin attributable to the parent company increased to 4.2%, up 0.5 ppts yoy.

The rising sales mix of Zeekr contributed significantly to the improvement in overall gross margin. In terms of expense ratios, the sales/administration/R&D expense ratios were 5.92%/1.88%/5.1%, respectively, representing yoy changes of -0.04/-0.39/+0.14 ppts. This was mainly due to increased investment in the R&D of new models and platforms, as well as a lower capitalisation ratio of R&D expenses.

Looking ahead, as the One Geely strategy continues to deepen, the cost reduction effect from declining expense ratios¡Xdriven by technology sharing and cost optimisation¡Xwill continue to materialise.

Investment Thesis

We revised our financial forecast and target price to HKD 26.6, equivalent to 12.5/10.8/8.4x PE ratio in 2026/2027/2028, and we give the rating of Accumulate. Closing price as at 15 April.

Geely's PE Band trend

""

Source: Wind, Company, Phillip Securities Hong Kong Research

Financial

"Financial

(Closing price as at 15 April)


Download PDF version...




Recommendation on 23-4-2026
RecommendationAccumulate
Price on Recommendation Date$ 24.040
Suggested purchase priceN/A
Target Price$ 26.600
Writer Info
Zhang Jing
(Analyst)
Tel: (+ 86 021-6351 2939)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]